MINERALYS THERAPEUTICS INC (MLYS) Stock Price & Overview
NASDAQ:MLYS • US6031701013
Current stock price
The current stock price of MLYS is 28.93 USD. Today MLYS is up by 0.52%. In the past month the price increased by 26.44%. In the past year, price increased by 116.87%.
MLYS Key Statistics
- Market Cap
- 2.385B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.37
- Dividend Yield
- N/A
MLYS Stock Performance
MLYS Stock Chart
MLYS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MLYS. When comparing the yearly performance of all stocks, MLYS is one of the better performing stocks in the market, outperforming 90.31% of all stocks.
MLYS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLYS. No worries on liquidiy or solvency for MLYS as it has an excellent financial health rating, but there are worries on the profitability.
MLYS Earnings
MLYS Forecast & Estimates
15 analysts have analysed MLYS and the average price target is 50.36 USD. This implies a price increase of 74.08% is expected in the next year compared to the current price of 28.93.
MLYS Groups
Sector & Classification
MLYS Financial Highlights
Over the last trailing twelve months MLYS reported a non-GAAP Earnings per Share(EPS) of -2.37. The EPS increased by 34.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.37% | ||
| ROE | -23.91% | ||
| Debt/Equity | 0 |
MLYS Ownership
MLYS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MLYS
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 76 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The company has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The company is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Company Info
IPO: 2023-02-10
MINERALYS THERAPEUTICS INC
150 N. Radnor Chester Rd., Suite F200
Radnor PENNSYLVANIA US
Employees: 76
Phone: 18883786240
MINERALYS THERAPEUTICS INC / MLYS FAQ
Can you describe the business of MINERALYS THERAPEUTICS INC?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 76 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The company has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The company is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
What is the current price of MLYS stock?
The current stock price of MLYS is 28.93 USD. The price increased by 0.52% in the last trading session.
Does MLYS stock pay dividends?
MLYS does not pay a dividend.
What is the ChartMill technical and fundamental rating of MLYS stock?
MLYS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about MINERALYS THERAPEUTICS INC (MLYS) stock?
15 analysts have analysed MLYS and the average price target is 50.36 USD. This implies a price increase of 74.08% is expected in the next year compared to the current price of 28.93.
Can you provide the sector and industry classification for MINERALYS THERAPEUTICS INC?
MINERALYS THERAPEUTICS INC (MLYS) operates in the Health Care sector and the Biotechnology industry.
When does MINERALYS THERAPEUTICS INC (MLYS) report earnings?
MINERALYS THERAPEUTICS INC (MLYS) will report earnings on 2026-05-11.